The Novo Group

A group of companies controlled by the Novo Nordisk Foundation

The Novo Group is a group of independent companies controlled by the Novo Nordisk Foundation. Novo Holdings serves as the holding company of the Group.

Through Novo Holdings, the Foundation owns the controlling stake in the two major companies of the Novo Group: Novo Nordisk A/S and Novozymes A/S, both of which are publicly listed. Novo Holdings owns more than 25% of the ordinary share capital of the two companies and controls more than 70% of the votes given our ownership of all the preferred (A) shares of Novo Nordisk and Novozymes.

In the case of Novo Nordisk and Novozymes, each preferred (A) share is allocated 10 votes and each ordinary (B) share one vote. The Foundation is obligated to maintain this controlling ownership in both companies.

Novo Nordisk Foundation

Novo Holdings

The Novo Group

Novo Nordisk

Novozymes

Novo Nordisk A/S

Novo Nordisk is a global healthcare company with more than 100 years of innovation and leadership in diabetes care. Novo Nordisk also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.

Headquartered in Denmark, Novo Nordisk A/S employs about 55.000 employees in 80 countries and markets its products in 168 countries. In 2022, Novo Nordisk A/S had revenue of USD 25,011 billion.

Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its American Depository Receipts (ADRs) are listed on the New York Stock Exchange (NVO).

Visit Novo Nordisk

Novo Nordisk A/S

Novo Nordisk is a global healthcare company with more than 100 years of innovation and leadership in diabetes care. Novo Nordisk also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.

Headquartered in Denmark, Novo Nordisk A/S employs about 55.000 employees in 80 countries and markets its products in 168 countries. In 2022, Novo Nordisk A/S had revenue of USD 25,011 billion.

Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its American Depository Receipts (ADRs) are listed on the New York Stock Exchange (NVO).

Visit Novo Nordisk

Novozymes A/S

Novozymes is the world leader in bioinnovation. Together with customers, partners and global society, the company improves industrial production and contributes to preserving natural resources and improving the quality of life. Novozymes’ natural solutions enhance and promote everything from removing trans-fats in food to advancing biofuels to power the world tomorrow.

Headquartered in Denmark, Novozymes A/S has more than 6,700 employees worldwide and markets more than 700 products in 140 countries. In 2022, Novozymes A/S had revenue of DKK 17,553 billion (EUR 2,3 billion).

Novozymes’ B shares are listed on NASDAQ OMX Copenhagen.

Visit Novozymes

Novozymes A/S

Novozymes is the world leader in bioinnovation. Together with customers, partners and global society, the company improves industrial production and contributes to preserving natural resources and improving the quality of life. Novozymes’ natural solutions enhance and promote everything from removing trans-fats in food to advancing biofuels to power the world tomorrow.

Headquartered in Denmark, Novozymes A/S has more than 6,700 employees worldwide and markets more than 700 products in 140 countries. In 2022, Novozymes A/S had revenue of DKK 17,553 billion (EUR 2,3 billion).

Novozymes’ B shares are listed on NASDAQ OMX Copenhagen.

Visit Novozymes

The Novo Group Charter

Present as well as future companies in the Novo Group must demonstrate willingness, ability and resolve to meet the following criteria:

company products and services make a significant difference in improving the way people live and work;
the company is perceived to be an innovator – in technology, in products, in services and/or in market approach;
the company is among the best in its business and a challenging place to work;
the company delivers competitive financial performance;

Companies in the Novo Group commit to:

value-based management;
open and honest dialogue with its stakeholders;
continuous improvement of financial performance, environmental performance and social performance;
reporting in accordance with relevant, internationally approved, conventions